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Abstract To quantify with in vivo OCT and histol-
ogy, the device/vessel interaction after implantation of
the bioresorbable vascular scaffold (BVS). We eval-
uated the area and thickness of the strut voids
previously occupied by the polymeric struts, and the
neointimal hyperplasia (NIH) area covering the end-
oluminal surface of the strut voids (NIHEV), as well as
the NIH area occupying the space between the strut
voids (NIHBV), in healthy porcine coronary arteries at
2, 3 and 4 years after implantation of the device.
Twenty-two polymeric BVS were implanted in the
coronary arteries of 11 healthy Yucatan minipigs that
underwent OCT at 2, 3 and 4 years after implantation,
immediately followed by euthanasia. The areas and
thicknesses of 60 corresponding strut voids previously
occupied by the polymeric struts and the size of 60
corresponding NIHEV and 49 NIHBV were evaluated
with both OCT and histology by 2 independent
observers, using a single quantitative analysis software
for both techniques. At 3 and 4 years after implanta-
tion, the strut voids were no longer detectable by OCT
or histology due to complete polymer resorption.
However, analysis performed at 2 years still provided
clear delineation of these structures, by both tech-
niques. The median [ranges] areas of these strut voids
were 0.04 [0.03–0.16] and 0.02 [0.01–0.07] mm2 by
histology and OCT, respectively. The mean (±SD)
thickness by histology and OCT was 220 ± 40 and
120 ± 20 lm, respectively. The median [ranges]
NIHEV by histology and OCT was 0.07 [0.04–0.20]
and 0.03 [0.01–0.08] mm2, while the mean (±SD)
NIHBV by histology and OCT was 0.13 ± 0.07 and
0.10 ± 0.06 mm2. Our study indicates that in vivo
OCT of the BVS provides correlated measurements of
the same order of magnitude as histomorphometry,
and is reproducible for the evaluation of certain
vascular and device-related characteristics. However,
histology systematically gives larger values for all the
measured structures compared to OCT, at 2 years post
implantation.
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Introduction
Bioresorbable coronary scaffolds are a novel
approach to the percutaneous treatment of coronary
artery disease. Recently, the everolimus-eluting bior-
esorbable vascular scaffold (BVS) (Abbott Vascular,
Santa Clara, Santa Clara, USA) has been studied in
the first-in-man ABSORB cohort A trial, which
demonstrated the feasibility and safety of this device,
with a rate of major adverse cardiac events of 3.4%
up to 3 years [1–3]. The BVS is composed of a
backbone of poly-L-lactide (PLLA), covered with the
polymer poly-D, L-lactide (PDLLA), containing and
controlling the release of the drug, everolimus
(Novartis, Basel, Switzerland). PLLA and PDLLA
degrade to lactic acid which is metabolized via the
Krebs’ cycle during the bioresorption process. The
radiolucent device is visualized on angiography by
radio-opaque platinum markers located at each end
[4]. The introduction of these new devices prompts us
to refine our methods of evaluation, using state-of-
the-art imaging modalities, such as optical coherence
tomography (OCT). This imaging technique has a
near-histological resolution (*15 lm), which makes
it ideal for studying the device/vessel interaction in
detail [5]. As the polymeric struts are translucent,
light-based imaging modalities are particularly suit-
able for this purpose. Up to now, histological
morphometry has been crucial in the evaluation of
the performance of new devices [6]. As histology is
limited to animal and human post-mortem studies, in
vivo assessment using OCT is highly desirable. This
porcine study was set up in 2006 with the goal to
evaluate the device/vessel interaction after implanta-
tion of the BVS at 2, 3 and 4 years, using OCT and
histology. The qualitative strut-related characteristics
with regards to the process of biodegradation were
published recently [7]. In this part of the study, we
sought to evaluate whether mimicking the histolog-
ical morphometric approach using OCT is feasible
and reproducible for the evaluation of the vascular
healing following implantation with the BVS.
Specifically, we sought to compare a number of
quantitative parameters assessed by ex vivo/‘‘post
processed’’ histology and in vivo/‘‘non-processed’’
OCT, in order to assess the agreement between these
techniques. These parameters include: the number
and size of the structures resembling struts, and
quantification of the tissue growth covering the
endoluminal surface and the tissue growth between
these structures.
Methods
Study sample and OCT imaging
Twenty two polymeric devices, BVS revision 1.0
(3 9 12 mm) were implanted in 11 healthy Yucatan
minipig coronary arteries, with a balloon: artery ratio
of 1.2:1. The BVS revision 1.0 has three main
components: the polymeric backbone, the polymeric
drug reservoir, and the antiproliferative drug, everol-
imus. The polymeric scaffold is balloon-expandable,
and is composed of a high molecular weight PLLA
with serpentine rings interconnected by links. The
scaffold body design is coated with a matrix of
PDLLA and everolimus in a 1:1 ratio. The device is
laser cut from an extruded tube and has two radio-
opaque platinum markers at both ends [8]. Since OCT
at 3 and 4 years following implantation displayed no
signal at the site where struts were expected to have
been previously implanted, we evaluated only the
devices available at 2 years follow-up. At this time
point, the PLLA backbone is almost completely
resorbed, as evidenced by gel permeation chroma-
tography, and histology shows accumulations of
proteoglycans (stained positively with Alcian blue)
at corresponding sites. By OCT, however, these
‘‘strut voids’’ appear as well delineated hyporeflective
foci. Since it is known that by OCT, immediately
after implantation, BVS polymeric struts appear as
black boxes with bright borders [1], these findings
indicate that OCT does not distinguish between the
BVS strut polymeric material and the provisional
matrix that replaces the strut after full bioresorption
[7]. Throughout the entire length of this manuscript,
we will use the term ‘‘strut void’’ to describe these
strut-like structures, previously occupied by the
polymeric material.
OCT was performed in vivo using the M2 CV
imaging system (LightLab Imaging, Westford, MA,
USA). In brief, the low-pressure HeliosTM occlusion
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balloon catheter was advanced distally to the region
of interest over a conventional 0.014 inch angioplasty
wire, which was then exchanged with the OCT
ImageWireTM. After calibration of the image wire by
correction of the Z-offset [9], the occlusion balloon
catheter was withdrawn proximally to the region of
interest, and inflated to 0.5–0.7 atmospheres. During
image acquisition, blood clearance was achieved by
manual continuous flushing with lactated Ringer’s
solution. Cross-sectional images were acquired at
15.6 frames/s, with an automatic pullback speed of
1 mm/s. Images were stored digitally for off-line
analysis.
Processing for histology and selection
of corresponding OCT and histology images
Animal sacrifice was performed immediately after
OCT imaging by intravenous sodium pentobarbital
infusion. The heart was explanted from the thoracic
cavity, the aorta clamped, and the coronary arteries
were pressure perfused at 100–120 mm Hg: first with
0.9% saline, followed by 10% neutral buffered
formalin for approximately 30 min. Hearts were then
immersed in formalin for complete fixation. Follow-
ing this, arteries were carefully dissected off the
heart. The location of the scaffolds was confirmed by
high-contrast film-based radiographs (Faxitron X-ray
Corp., Lincolnshire, IL, USA) and the specimens
were dehydrated in a graded series of ethanol. The
scaffolded segments were then embedded in methyl
methacrylate (MMA) for polymerization [4]. The
MMA block was sawed into three 4 mm segments,
and three cross-sections were cut using a rotary
microtome with a tungsten carbide blade: one at the
proximal scaffold segment, 2 mm distal to the
proximal metallic marker; one at the middle segment,
6 mm distal to the proximal marker; and one at the
distal scaffold segment, 2 mm proximal to the distal
marker. Finally, the samples were mounted and
stained with hematoxylin and eosin (HE) and/or
elastic Van Gieson (EVG).
Corresponding OCT cross-sections were selected
by one observer (YO), using the distances from the
platinum markers and anatomical landmarks, such as
side branches, as references. Two observers (BG,
MR) identified the corresponding structures of inter-
est. The quantitative analysis was performed with the
observers blinded to each other’s results, as well as to
the correspondence between the OCT and histology
images. We assumed that the sharp boundary of the
strut voids by histology corresponded to the sharply
delineated bright borders of the ‘‘black boxes’’ by
OCT.
Quantitative analysis of OCT and histology
images
OCT and histology images were analyzed with the
QCU-CMS software version 4.64 (Laboratory of
Clinical and Experimental Image processing, Leiden,
The Netherlands), which has previously been shown
to provide correlated quantitative measurements as
compared to the LightLab software [20]. Once images
were uploaded, calibration was performed: for OCT,
the diameter (0.36 mm) of the image wire was used,
whilst histology images were calibrated using the
scale bar provided by the pathologist. After calibra-
tion of the images, the following parameters were
quantified: (1) the number of strut voids previously
occupied by the polymeric struts (2) the lumen area
and the area encompassing the abluminal surfaces of
these strut voids; (3) the area and thickness of these
strut voids and (4) the neointimal hyperplasia (NIH)
area covering the endoluminal surface (NIHEV) and
the NIH area between the strut voids (NIHBV)
(Fig. 1). To be more specific, the measurements were
performed in the following way (Figs. 1 and 2): 1.
‘‘Scaffold’’ area: after manual localization of the strut
voids by setting a green circle at the mid point of their
abluminal surfaces, these points were connected
automatically by a trace line placed by the software.
In addition, the center of gravity of the scaffold area
was determined automatically by the software. 2.
Lumen area: the lumen contour was automatically
traced by the software; 3. The area of the strut void:
this was manually demarcated by following the
contour of these structures; 4. NIHBV: in order to
demarcate the NIH areas laterally, we used the angle
tool of the software, which takes the center of gravity
of the scaffold as reference.
The rays of the angle tool were placed as help
lines, at the edges of every strut void creating an area
between these which was limited axially by the
scaffold line and the lumen contour and laterally by
the help lines (Fig. 1 and 2); 5. NIHEV: was defined
as the area limited by the ‘‘help lines’’ placed at the
edges of the strut voids, their endoluminal surfaces,
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and the lumen area contour; 6. Neointimal thickness:
this was measured from the mid point of the
endoluminal surface of the strut voids to the lumen
contour, along a line projected through the center of
gravity of the scaffold; 7: Strut void thickness: this
was assessed by measuring the distance between the
mid points of the endoluminal and abluminal surfaces
of the strut voids.
Statistical analysis
Statistical analyses were performed with SPSS,
version 16 (SPSS Inc.,Chicago, IL, USA). Discrete
variables are presented as counts and percentages,
and continuous variables as mean ± standard
deviations, or medians and interquartile ranges or
ranges (minimum–maximum). The Pearson’s corre-
lation coefficient (r2) was computed to compare OCT
and histological measurements. Bland–Altman plots,
displaying the systematic (mean absolute difference)
and random (95% limits of agreement) errors, and the
interclass correlation coefficient for absolute agree-
ment (ICCa) and consistency (ICCc) were used to
assess the agreement between techniques. Inter-
observer variability was assessed using the correla-
tion coefficient (r2). A two-sided p-value B 0.05 was
considered significant.
Results
A total of six corresponding cross-sections were
available for the purpose of this study (Fig. 3).
Histology displayed 75 strut voids previously occu-
pied by the polymeric struts whilst OCT showed only
60. Fifteen of these strut voids by histology could not
be identified in the OCT images due to non-uniform
rotational distortion, marginalization of the image
wire into a side branch and a long distance to the
image wire, together with a low light incidence angle
resulting in a high light attenuation (Fig. 4). Thus, a
total of 60 corresponding strut voids were included in
the analysis. In only 1 of 6 frames were all
corresponding strut remnants visualised by both
OCT and histology with the consequence that the
lumen and scaffold area was only accurately assessed
in this frame (OCT: 2.78 and 5.14 mm2; histology:
1.02 and 4.40 mm2, for lumen and scaffold area,
respectively). The ratio between the lumen area and
stent area for the OCT was 0.54 while for histology
was 0.23 and the % area obstruction of the scaffold
for OCT was 45% while for histology 76%. Apart
from the strut voids that were not adequately
visualized, all images were successfully analysed
using the histomorphometrical methodology with the
dedicated off-line software. Table 1 and Fig. 5 show
the descriptive statistics and Bland–Altman plots for
the different parameters measured with OCT and
histology. The average difference and 95% limits of
agreement were: for the strut area: 0.03 [0.07;
-0.01], for the strut thickness: 0.10 [0.18; 0.02], for
the NIHEV: 0.04 [0.10; -0.02] and for the NIHBV:
0.03 [0.21; 0.15]. In general, histomorphometry
provided larger values for all parameters compared
Fig. 1 Schematic representation of the quantitative analysis.
Panel a The thick red line represents the vessel wall; the black
continuous line, the lumen contour; black squares strut voids
previously occupied by the polymeric struts; and the blue
dotted line the abluminal ‘‘scaffold’’ area. The red cross
indicates the center of gravity of the remnants of the scaffold,
which was provided automatically by the software after manual
indication of the mid point of the abluminal surfaces of the
strut-like structures. The center of gravity point was used to
place ‘‘the help lines’’ (black dotted lines) for the measurement
of the neointimal hyperplasia area covering the endoluminal
surface of these structures (red area), and the neointimal
hyperplasia area between these structures (green area). The
neointimal thickness (red arrow) was measured from the
endoluminal surface of the strut voids to the lumen contour,
along a line projected through the center of gravity of the
scaffold and the mid point of the abluminal surface of these
structures. The strut void thickness (white arrow) was
measured in a similar way
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to OCT. Interobserver variability was evaluated for
all variables assessed with histology and OCT
(Fig. 6). The mean (SD) differences between observ-
ers were negligible for the parameters measured in
the histological sections (area and thickness of strut
voids 0.00 (0.00) mm2 and 0 (30) lm, repcetively;
NIHEV 0.00 (0.00) mm
2, and NIH BV 0.00 (0.01)
mm2), as well as for those assessed in the OCT cross-
sections (for area and thickness of strut voids: 0.00
(0.00) mm2 and 0 [10] lm, respectively; for NIHEV
0.00 (0.01) mm2, and NIHBV -0.03 (0.01) mm
2).
The Lin’s correlation coefficient interpreted by the
ICCc and ICCa for the area of strut voids were: 0.34
[95% confidence interval (CI): 0.10–0.55], P \ 0.004
and 0.18 [95% CI: -0.08 to 0.43], P \ 0.004; for the
thickness of these structures: 0.08 [95% CI: -0.18 to
0.33], P = 0.271 and 0.01 [95% CI: -0.03 to 0.07],
P = 0.271; for NIHEV: 0.39 [95% CI: 0.15–0.59],
P \ 0.001 and 0.19 [95% CI: -0.09 to 0.46], P \
0.001; and for NIHBS: -0.03 [95% CI: -0.29 to
0.29], P = 0.50 and -0.03 [95% CI: -0.27 to 0.28],
P = 0.50.
The Pearson’s correlation coefficient (r2) for the
interobserver variability for the histology assessment
was: for the thickness and area of the strut voids
thickness: r2 = 0.89 and r2 = 0.78, respectively; for
NIHEV: r
2 = 0.87; and for NIHBV: r
2 = 0.86 (P \
0.001 for all analyses). Corresponding results for the
OCT measurements were: for thickness and area of
strut voids: r2 = 0.70 and r2 = 0.57, respectively; for
NIHEV: r
2 = 0.67; and for NIHBV: r
2 = 0.66 (P \
0.001 for all analyses).
Fig. 2 Demonstration of quantitative measurements by histol-
ogy and OCT. Panels A and B show the inverted grey scale and
color histology images, respectively, with superimposed
quantitative measurements (green lines in A), and panels
C and D, the corresponding grey scale and sepia OCT, with the
respective measurements (only C). The red lines are provided
by the software, and are projected from the center of gravity of
the scaffold through the mid points of the abluminal surfaces of
the struts
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Fig. 3 Cross-sections of corresponding OCT and histology of the left anterior descending artery (A/G, B/H, C/I), and the right
coronary artery (D/J, E/K, F/L). Histology specimens are stained with elastic Van Gieson
Fig. 4 Factors precluding identification of some of the strut
voids in corresponding OCT and histology images. Panels A–
C demonstrate how non-uniform rotational distortion (A),
marginalisation of the image wire into a side branch (B), and a
long distance between the image wire and black boxes preclude
visualisation of these strut voids by OCT, as compared to
corresponding histology (D–F). Due to the lack of visualization
of these structures, abluminal scaffold areas could not be
accurately assessed. In order to obtain reproducible measure-
ments, it was before the analysis decided to trace the scaffold
area only at the sites of black boxes that are visualized, with the
consequence of an underestimation of the ‘‘true’’ OCT scaffold
area
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Discussion
In the present study, we performed a quantitative
analysis of in vivo OCT images of the remnants of
bioresorbable vascular scaffolds at 2 years following
implantation, using a methodology similar to the
morphometric approach used with histology. The
main findings of this pilot study are: 1. Histology
appears to systematically give larger values, when
compared with OCT; 2. the approach similar to
histomorphometry for quantitative analysis of OCT
images is feasible and reproducible for the evaluation
Table 1 Descriptive statistics of all parameters measured by
OCT and histology
OCT Histology
Area of the strut voids,
mm2
0.02 (0.01–0.07) 0.04 (0.03–0.16)
Thickness of the strut
voids
120 (70–180) 220 (120–350)
NIHBV, mm
2 0.03 (0.01–0.08) 0.07 (0.04–0.20)
NIHEV, mm
2 0.09 (0.01–0.27) 0.13 (0.01–0.31)
NIH neointimal hyperplasia, BV between the voids, EV
endoluminal surfaces of the voids, values are median (range)
Fig. 5 Bland-Altman plots depicting the agreement between
techniques for the evaluation of the area (panel A) and
thickness (panel B) of the strut voids previously occupied by
the polymeric struts, the neointimal hyperplasia area covering
the endoluminal surface of these voids (panel C), and the
neointimal hyperplasia area between the voids (panel D), with
histology and OCT
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at follow up after implantation of the BVS; and 3.
despite the use of anatomical landmarks and intra-
scaffold radiopaque markers to identify correspond-
ing cross-sections, higher numbers of strut voids were
visualized by histology than by OCT.
Differences in quantitative measurements
between OCT and histology
The observation that quantitative measurements by
histology and OCT may differ is not new, as previous
studies have suggested that histological processing
may induce a certain degree of artifacts related to
formalin fixation and dehydration [10]. Surprisingly
however, our study showed that all morphological
characteristics analyzed were systematically larger by
histology as compared to OCT. More specifically, the
strut void area, strut void thickness, NIHEV and
NIHBV were 100%, 83%, 130% and 44% larger by
histology compared to OCT, respectively. Several
factors may have contributed to this difference. The
first involves the calibration of the OCT image wire
by adjustment of the Z-offset before image acquisi-
tion, as well as calibration of the scaling of OCT and
histology images before analysis, which are crucial
for any quantitative measurement. In the present
study, these were all performed according to current
standards [9]. Secondly, differences can potentially
be related to the application of different analysis
softwares for different techniques. We tried to
circumvent this by utilizing the same software, as
well as by using semi-automatic approaches, for all
analyses, which was evidenced in the good interob-
server reproducibility seen. Nevertheless, the quanti-
tative results by histology were systematically larger
than by OCT, as compared to previous studies, even
if these applied different softwares for the different
techniques [11, 12]. Other interfering factors are
therefore likely to be involved. For the NIH areas, our
results resemble those reported by Murata et al. and
Templin et al., who found that histology estimated
the NIH areas covering metallic stents slightly higher
than OCT, at 28 and 90 days, and at 10, 14 and
28 days, respectively [13, 14]. However, in our study,
the overestimation by histology was greater. This
may be related to the combined differences in: the
mechanical constraints imparted on the tissue
between the bioresorbable vascular scaffold as
compared to metallic stents; in the tissue composition
at time point of examination (2 years), which
includes a higher proportion of collagen and smooth
muscle cells as compared to time points less than
90 days [15]; and in the composition of the strut
voids which, as shown by Onuma et al., are replaced
by highly water-containing acid mucopolysacharides
material, which stains positively with Alcian Blue, at
this time point [7]. Further, previous studies have
indicated that formaldehyde, which we used for tissue
fixation, can cause dimensional changes that are
dependent on the composition of the tissue (for
example causing swelling in liver tissue and shrink-
age in muscle tissue), the pH of the tissue, and the
temperature and concentration of the fixative [10]. In
addition to tissue fixation, dehydration with ethanol,
embedding and polymerization in MMA, and sub-
sequent deplastization likely further impacted the
tissue dimensions obtained histologically. Consider-
ing the contrasting nature of the tissues at late follow-
up of the BVS, namely the proteoglycan-rich tissue
replacing pre-existing struts compared to the sur-
rounding smooth muscle cell and collagen-dense
tissue of the arterial wall, these tissue-specific
dimensional changes are especially notable at fol-
low-up after implantation of the BVS. This is
supported by the qualitative results regarding the
histological appearance of the strut-like structures at
2 and 3 years. At 2 years, the strut voids appear more
spherical, having a highly water-containing proteo-
glycan, while they are contracted and almost com-
pletely coalesced into the arterial wall at 3 years
(Fig. 6) [7]. Considering this, it is likely that the
proteoglycan-based nature of strut foci at 2 years
resulted in their swelling as an artifact of histological
processing.
The fact that OCT was performed in vivo, when
the vessel has a tonus and is naturally pressurized,
may also explain some of the discrepancies, although
efforts were made to pressurize vessels during
histology preparation. However, the most plausible
explanation involves the attempt to correspond OCT
and histology cross-sections, which depends on the
orientation of the OCT image wire relative to the
vessel curvature and relative to the location in the
vessel lumen, which in turn influence how the OCT
‘‘biotome’’ cross-sects the tissue and the scaffold.
The difficulty finding completely corresponding
cross-sections may be further affected by the
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differences in slice thicknesses of the samples
provided by the different techniques. For histology,
the minimum slice thickness possible to obtain, is in
the range of 4–5 lm with a sampling interval of
100 lm [16], and depends on the microtome, while
the minimum frame thickness available with the OCT
system used in the present study is 60 lm and
depends on the longitudinal sampling distance, which
is in turn related to the frame rate (15.6 frames/s) and
the pullback speed (1 mm/s). Nevertheless, it should
be stressed that wherever possible, efforts were made
to secure corresponding cross-sections by histology
and OCT using the scaffold platinum markers and
anatomical structures, as landmarks. Thus, our report
highlights some of the difficulties that may be
encountered in this type of study, which are important
to acknowledge (Fig. 7).
Consideration of technical aspects with OCT
imaging
Although efforts were made to obtain matched cross-
sections between OCT and histology using land-
marks, we found a higher density of strut voids by
histology than by OCT. In addition to the factors
mentioned above, we noticed that the intrinsic
properties of the OCT technology related to the use
of light also influenced our analysis. By marginali-
zation of the light source, causing an acute incidence
angle of the light on the vessel wall, as well as by the
relatively low scan diameter of the employed time
domain-OCT system (7 mm) compared to newer
generation frequency domain (FD)-OCT systems
(10 mm), visualisation of the strut voids along the
entire 360 degree vessel circumference was hindered
Fig. 6 Linear regression analysis plots depicting the interob-
server variability for the evaluation of the area and thickness of
the strut voids, the neointimal hyperplasia area covering the
endoluminal surface of these voids, and the neointimal
hyperplasia area between the voids, with histology (panels
A–D) and OCT (panels E–H), respectively
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(Fig. 3B, C), which prevented the identification of
these structures and the accurate delineation of the
abluminal scaffold area, as well as delineation of the
lumen area. Nevertheless, the only available accurate
corresponding lumen and scaffold areas by OCT and
histomorphometry showed that measurements by
OCT were larger than those by histology, which is
in line with previous studies [11–13]. Despite the
potential advantages of in vivo ‘‘non-processed’’
OCT, the presence of non-uniform rotational distor-
tion, which is related to vessel tortuosity, as well as
the presence of artefacts due to heart motion in
systole and diastole, further complicated the selec-
tion of perfectly corresponding frames. The new
generation FD-OCT which has a much higher frame
rate, allowing a higher pullback-speed without sig-
nificant loss in longitudinal sampling density [14, 17,
18], promises to overcome some of these issues,
together with recent advances allowing retrospective
reconstruction of gated OCT acquisitions [19]. How-
ever, these technologies were not available at the
time of data acquisition.
Histomorphometry-like analysis with OCT
Onuma et al. recently described a qualitative analysis
of OCT images of the polymeric struts of the BVS.
As opposed to that analysis, our study focused on the
evaluation of the quantitative tissue response around
the strut voids previously occupied by the polymeric
struts in terms of neointimal hyperplasia between and
on the endoluminal surface of these, which we found
to be feasible and reproducible, with a good interob-
server reproducibility. Despite the mentioned issues
regarding comparison between OCT and histology,
OCT represents at present the in vivo imaging
modality with the highest resolution, which enables
Fig. 6 continued
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us to evaluate fine details in the assessment of the
device/vessel interaction.
Study limitations
Our initial goal was to assess the morphometric
parameters of the remnants of the device implanted
with OCT at 2, 3, and 4 years following implanta-
tion. As part of the degradation process, the number
of bioresorbable struts identified by OCT decreased
with time. We now know that the polymeric struts
are completely resorbed and replaced by proteogly-
cans by 2 years. However, this respective time point
could not be foreseen at the time of planning of the
study. For the comparison of different measurements
by OCT and histology, it was necessary to select a
time point where strut-like structures (strut voids) are
fully visible with OCT. Consequently, specimens at
3 and 4 years could not be included in this study,
wherefore the sample size was relatively small. We
cannot dismiss the possibility that the low sample
size could, to some extent, explain the relatively
large distribution of individual parameters. Never-
theless, we believe that the findings of this pilot
study are interesting as they represent our initial
quantitative experience with the novel bioresorbable
technology, and may serve as a guide to the planning
of future trials with corresponding OCT and histo-
morphometry to evaluate bioresorbable vascular
scaffolds.
Fig. 7 Histological examples of the appearance of strut voids
at 2 and 3 years following implantation of the bioresorbable
vascular scaffold. Panels A–D show strut voids at 2 and 3 years
follow-up, respectively. At 2 years, the proteoglycan-rich
matrix appears to collapse in the middle of the void upon
histological preparation, giving a spherical appearance, while
the matrix at 3 years is coalesced with the neointima of the
vessel wall, giving the impression that the borders of the
contents of the void are better held together with the neointima.
Panels A and C are stained with hematoxylin and eosin, while
panels B and D are stained with Alcian blue. Reproduced from
Onuma et al. Circulation 2010
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Conclusion
The present pilot study showed that an approach for
quantitative analysis of OCT images akin to histo-
morphometry is feasible and reproducible for the
evaluation of the vascular healing at follow up after
implantation of the BVS and that corresponding OCT
and histomorphometry provide results of the same
order of magnitude. Despite the use of landmarks to
identify corresponding cross-sections, histology sys-
tematically provided larger measurements for all
studied parameters. Whether this is related to factors
influencing acquisition and processing of images, or
the bioresorbable nature of the device, requires
further investigation, for example using the new-
generation FD-OCT, and a larger sample analysed
with a higher sampling density.
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